外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析

doi:10.11904/j.issn.1002-3070.2022.06.010

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (6): 544-550.doi: 10.11904/j.issn.1002-3070.2022.06.010

外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析

徐子涵¹, 于国华², 聂玉辉¹, 孙蒙蒙¹, 丰慧¹, 刘淑真²

1.潍坊医学院临床医学院(潍坊 261063);
2.潍坊市人民医院肿瘤内科

收稿日期:2022-05-20 修回日期:2022-10-11 出版日期:2022-12-28 发布日期:2023-01-06
通讯作者: 刘淑真,E-mail:liushuzhen_wf@163.com
作者简介:徐子涵,女,(1997-),硕士研究生,从事恶性肿瘤的临床及基础研究

Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome

XU Zihan¹, YU Guohua², NIE Yuhui¹, SUN Mengmeng¹, FENG Hui¹, LIU Shuzhen²

1. Clinical Medical College,Weifang Medical University,Weifang 261053,China;
2. Department of Oncology,Weifang People′s Hospital

Received:2022-05-20 Revised:2022-10-11 Online:2022-12-28 Published:2023-01-06

摘要/Abstract

摘要： 目的探讨NLR、PLR和LDH检测对晚期非小细胞肺癌(NSCLC)发生免疫相关不良反应(irAEs)的预测作用,并分析其与生存结局的相关性。方法回顾性分析2017年1月1日—2021年1月1日在潍坊市人民医院接受PD-1/PD-L1抑制剂治疗的169例晚期NSCLC患者临床资料,将169例患者分为irAEs组(n=61)和非irAEs组(n=108),比较两组临床资料,绘制ROC曲线确定基线外周血参数预测irAEs发生的临界值,多因素logistic回归分析外周血标志物与irAEs发生的关系,使用Cox回归模型分析无进展生存期(PFS)和总生存期(OS)的影响因素。结果 irAEs组患者的基线外周血NLR、PLR较非irAEs组低,LDH较非irAEs组高(P＜0.05);治疗前NLR、PLR、LDH预测irAEs发生的最佳临界值分别为3.18(AUC=0.80)、181.56(AUC=0.62)和209.50(AUC=0.63),多因素logistic回归分析显示低NLR和高LDH是irAEs发生的独立危险因素(P＜0.05);低NLR组、低PLR组和低LDH组的PFS及OS均显著优于高NLR组、高PLR组和高LDH组(P＜0.05);Cox回归模型显示高NLR、高PLR和高LDH是PFS及OS的独立危险因素。结论 NLR、LDH对晚期NSCLC患者irAEs的发生具有预测价值,高NLR、高PLR和高LDH与晚期NSCLC免疫治疗的预后不良相关。

关键词: 非小细胞肺癌, 外周血标志物, 免疫相关不良反应, 预测, 预后

Abstract: Objective The aim of this study was to investigate the predictive effect of NLR, PLR and LDH on immune-related adverse events(irAEs)in advanced non-small cell lung cancer(NSCLC), and to analyze their correlation between them and survival outcomes.Methods Clinical data of 169 patients with advanced NSCLC who were treated with PD-1/PD-L1 inhibitor in Weifang People′s Hospital from January 1, 2017 to January 1, 2021 were retrospectively analyzed.These patients were divided into the irAEs group(n=61)and non-irAEs group(n=108).The clinical data of the two groups were compared.Receiver operating characteristic(ROC)curve was drawn to determine the threshold value of baseline peripheral blood parameters to predict the occurrence of irAEs.Multivariate logistic regression analysis was used to explore the relationship between peripheral blood markers and the incidence of irAEs.Cox regression model was used to analyze the influencing factors of progression-free survival(PFS)and overall survival(OS).Results The baseline peripheral blood NLR and PLR of patients in the irAEs group were lower than those in the non-irAEs group, and the LDH was higher than those in the non-irAEs group(P＜0.05).The best critical values of NLR, PLR and LDH before treatment for predicting the occurrence of irAEs were 3.18(AUC=0.80), 181.56(AUC=0.62), and 209.50(AUC=0.63), respectively.Multivariate logistic regression analysis showed that low NLR and high LDH were independent risk factors for the occurrence of irAEs(P＜0.05).The PFS and OS in low NLR, low PLR and low LDH groups were significantly better than those in the high NLR, high PLR and high LDH groups(P＜0.05).Cox regression model showed that high NLR, high PLR and high LDH were independent risk factors for PFS and OS.Conclusion NLR and LDH can predict the occurrence of irAEs in advanced NSCLC patients.High NLR, high PLR, and high LDH are associated with poor prognosis of immunotherapy for advanced NSCLC.

Key words: Non-small cell lung cancer, Peripheral blood markers, Immune-related adverse reactions, Prediction, Prognosis

中图分类号:

R734.2

徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.

XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome[J]. Journal of Practical Oncology, 2022, 36(6): 544-550.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.06.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I6/544

参考文献

1 Thai AA,Solomon BJ,Sequist LV,et al.Lung cancer[J].Lancet,2021,398(10299):535-554.
2 Reck M,Remon J,Hellmann MD.First-Line immunotherapy for non-small-cell lung ancer[J].J Clin Oncol,2022,40(6):586-597.
3 Borghaei H,Gettinger S,Vokes EE,et al.Five-year outcomes from the randomized,phase iii trials checkmate 017 and 057:nivolumab versus docetaxel in previously treated non-small-cell lung cancer[J].J Clin Oncol,2021,39(7):723-733.
4 Xu C,Chen YP,Du XJ,et al.Comparative safety of immune checkpoint inhibitors in cancer:systematic review and network meta-analysis[J].BMJ,2018,363:k4226.
5 Russo A,Franchina T,Ricciardi GRR,et al.Baseline neutrophilia,derived neutrophil-to-lymphocyte ratio(dNLR),platelet-to-lymphocyte ratio(PLR),and outcome in non small cell lung cancer(NSCLC)treated with Nivolumab or Docetaxel[J].J Cell Physiol,2018,233(10):6337-6343.
6 Mezquita L,Auclin E,Ferrara R,et al.Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J].JAMA Oncol,2018,4(3):351-357.
7 Shaul ME,Fridlender ZG.Tumour-associated neutrophils in patients with cancer[J].Nat Rev Clin Oncol,2019,16(10):601-620.
8 Haemmerle M,Stone RL,Menter DG,et al.The platelet lifeline to cancer:challenges and opportunities[J].Cancer Cell,2018,33(6):965-983.
9 Chen DS,Mellman I.Oncology meets immunology:the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.
10 Ding J,Karp JE,Emadi A.Elevated lactate dehydrogenase(LDH)can be a marker of immune suppression in cancer:interplay between hematologic and solid neoplastic clones and their microenvironments[J].Cancer Biomark,2017,19(4):353-363.
11 Haanen J,Carbonnel F,Robert C,et al.Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):264-266.
12 Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
13 Khoja L,Day D,Wei-Wu Chen T,et al.Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors:a systematic review[J].Ann Oncol,2017,28(10):2377-2385.
14 Peravali M,Gomes-Lima C,Tefera E,et al.Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses[J].World J Clin Oncol,2021,12(2):103-114.
15 Pavan A,Calvetti L,Dal Maso A,et al.Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors[J].Oncologist,2019,24(8):1128-1136.
16 Eun Y,Kim IY,Sun JM,et al.Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab[J].Sci Rep,2019,9(1):14039.
17 Capone M,Giannarelli D,Mallardo D,et al.Baseline neutrophil-to-lymphocyte ratio(NLR)and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab[J].J Immunother Cancer,2018,6(1):74.
18 Guida M,Bartolomeo N,Quaresmini D,et al.Basal and one-month differed neutrophil,lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma[J].J Transl Med,2022,20(1):159.

[1]	教冲, 史雨鑫, 徐浩译, 马斌林, 董朝. 二甲双胍对不同亚型乳腺癌伴2型糖尿病患者预后影响的研究[J]. 实用肿瘤学杂志, 2022, 36(6): 531-537.
[2]	杨磊, 张正凤, 王大榛, 娄长杰. 基于真实世界的晚期食管鳞癌一线标准化疗联合免疫检查点抑制剂对比标准化疗的回顾性对照研究[J]. 实用肿瘤学杂志, 2022, 36(6): 538-543.
[3]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[4]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.
[5]	董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355.
[6]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[7]	王洪英, 李岩, 韩鑫浩, 魏孝礼, 贾慧珣, 袁文娟, 张秋菊. 基于免疫相关lncRNAs的胃癌早期诊断和预后风险模型的构建和验证[J]. 实用肿瘤学杂志, 2022, 36(2): 119-126.
[8]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.
[9]	张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.
[10]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[11]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[12]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[13]	邬丽婷, 李大兵, 邓小霞, 李柏松. 2013—2020年重庆市北碚区胃癌疾病负担变化趋势及预测[J]. 实用肿瘤学杂志, 2021, 35(6): 495-499.
[14]	罗雯, 贾莉, 张佳文, 王冬杰, 孔英君. circRNA MYO1C对肺癌细胞自噬和肿瘤干细胞分化的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 500-505.
[15]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.

外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析

Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价